Acologix drops $115M IPO
Acologix, a Hayward, Calif., biotech focused on treating bone and kidney disease, withdrew an IPO that it had hoped would raise as much as $115 million. See our story at VentureBeat Life Sciences.
Next Story: Compete, Inc, raises money to stay competitive
Previous Story: Bone and kidney treater Acologix abandons $115M IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.